These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16164982)

  • 21. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.
    Golshayan AR; Jin T; Maciejewski J; Fu AZ; Bershadsky B; Kattan MW; Kalaycio ME; Sekeres MA
    Br J Haematol; 2007 Apr; 137(2):125-32. PubMed ID: 17391492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.
    Mitsopoulos E; Zanos S; Ginikopoulou E; Kyriklidou P; Meimaridou D; Sakellariou G
    Am J Kidney Dis; 2006 Jul; 48(1):114-21. PubMed ID: 16797393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog.
    Takami A; Nakao S; Ontachi Y; Yamauchi H; Matsuda T
    Int J Hematol; 1999 Jan; 69(1):24-6. PubMed ID: 10641439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis.
    Boas SR; Hageman JR; Ho LT; Liveris M
    J Cyst Fibros; 2009 Jul; 8(4):270-2. PubMed ID: 19447079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL; Hristova M; Ho LT; Sprague SM
    Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis.
    Hiremath GS; Cettomai D; Baynes M; Ratchford JN; Newsome S; Harrison D; Kerr D; Greenberg BM; Calabresi PA
    Mult Scler; 2009 Jun; 15(6):735-40. PubMed ID: 19383644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of paricalcitol on proteinuria.
    Aperis G; Paliouras C; Zervos A; Arvanitis A; Alivanis P
    J Ren Care; 2011 Jun; 37(2):80-4. PubMed ID: 21561543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.
    Petrich A; Kahl B; Bailey H; Kim K; Turman N; Juckett M
    Leuk Lymphoma; 2008 Jan; 49(1):57-61. PubMed ID: 18203012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydrotachysterol and vitamin D resistance in renal failure.
    Sagar S; Estrada RL; Kaye M
    Arch Intern Med; 1972 Nov; 130(5):768-9. PubMed ID: 4538857
    [No Abstract]   [Full Text] [Related]  

  • 40. Vitamin B(12)-responsive pancytopenia mimicking myelodysplastic syndrome.
    Kim M; Lee SE; Park J; Lim J; Cho BS; Kim YJ; Kim HJ; Lee S; Min CK; Kim Y; Cho SG
    Acta Haematol; 2011; 125(4):198-201. PubMed ID: 21252496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.